Erste Asset Management GmbH Acquires Shares of 2,184,900 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Erste Asset Management GmbH bought a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 2,184,900 shares of the biopharmaceutical company's stock, valued at approximately $97,199,000. Agios Pharmaceuticals accounts for 1.2% of Erste Asset Management GmbH's holdings, making the stock its 12th largest position. Erste Asset Management GmbH owned about 3.83% of Agios Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of AGIO. Acadian Asset Management LLC acquired a new stake in Agios Pharmaceuticals during the second quarter valued at $37,000. Quest Partners LLC acquired a new stake in shares of Agios Pharmaceuticals during the 2nd quarter valued at about $40,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Agios Pharmaceuticals by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company's stock valued at $94,000 after buying an additional 363 shares in the last quarter. CWM LLC increased its holdings in Agios Pharmaceuticals by 554.7% in the third quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company's stock worth $96,000 after buying an additional 1,836 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in Agios Pharmaceuticals during the third quarter valued at approximately $146,000.

Insider Transactions at Agios Pharmaceuticals

In other news, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the sale, the chief financial officer now owns 20,158 shares of the company's stock, valued at approximately $988,346.74. This trade represents a 11.20 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.93% of the stock is currently owned by corporate insiders.

Agios Pharmaceuticals Trading Up 1.2 %

AGIO traded up $0.73 during midday trading on Friday, reaching $59.39. The company's stock had a trading volume of 237,613 shares, compared to its average volume of 729,884. Agios Pharmaceuticals, Inc. has a twelve month low of $20.96 and a twelve month high of $62.58. The stock has a market cap of $3.39 billion, a P/E ratio of 5.23 and a beta of 0.75. The company has a fifty day simple moving average of $48.68 and a 200 day simple moving average of $45.49.

Analysts Set New Price Targets

Several analysts have commented on the stock. StockNews.com raised shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, November 9th. Raymond James reiterated an "outperform" rating and issued a $51.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Leerink Partnrs lowered Agios Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, September 27th. Scotiabank upped their price target on Agios Pharmaceuticals from $51.00 to $53.00 and gave the stock a "sector outperform" rating in a research note on Friday, November 1st. Finally, Leerink Partners lowered Agios Pharmaceuticals from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $60.00 to $56.00 in a report on Friday, September 27th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $52.33.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.